An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer

Kelly V. Ruggles¹, Zuojian Tang¹, Xuya Wang¹, Himanshu Grover¹, Manor Askenazi², Jennifer Teubl¹, Song Cao³, Michael D. McLellan³, Karl R. Clauser⁴, David L. Tabb⁵, Philipp Mertins⁴, Robbert Slebos⁵, Petra Erdmann-Gilmore³, Shunqiang Li³, Harsha P. Gunawardena⁶, Ling Xie⁶, Tao Liu⁷, Jian-Ying Zhou⁸, Shisheng Sun⁸, Katherine A. Hoadley⁶, Charles M. Perou⁶, Xian Chen⁶, Sherri R. Davies³, Christopher A. Maher³, Christopher R. Kinsinger⁹, Karen D. Rodland⁷, Hui Zhang⁸, Zhen Zhang⁸, Li Ding³, R. Reid Townsend³, Henry Rodriguez⁹, Daniel Chan⁸, Richard D. Smith⁷, Daniel C. Liebler⁵, Steven A. Carr⁴, Samuel Payne⁷*, Matthew J. Ellis³*, David Fenyő¹*.

¹New York University School of Medicine, New York, NY
²Biomedical Hosting, LLC, Arlington, MA
³Washington University in St. Louis, St. Louis, MO
⁴Broad Institute of Harvard and MIT, Cambridge, MA
⁵Vanderbilt University School of Medicine, Nashville, TN
⁶University of North Carolina School of Medicine, Chapel Hill, NC
⁷Pacific Northwest National Laboratory, Richland, WA
⁸Johns Hopkins University, Baltimore, MD
⁹Office of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD.

*Correspondence should be addressed to:
Dr. Samuel Payne, Pacific Northwest National Laboratory, 902 Battelle Boulevard, Richland, WA 99532
E-mail: Samuel.Payne@pnnl.gov
Dr. Matthew J. Ellis, Washington University in St. Louis, 660 South Euclid Ave, St Louis, MO 63110
Email: mellis@dom.wustl.edu;
Dr. David Fenyő, New York University School of Medicine, 227 East 30th Street, New York, NY 10016. Email: david@fenyolab.org

**Running Title:** Sensitivity Analysis of Proteogenomic Mapping
**Abbreviations:**

iTRAQ: Isobaric Tags for Relative and Absolute Quantitation

LF: Label Free

LR: Low Resolution

HR: High Resolution

MPS: Massively Parallel Sequencing

NGS: Next Generation Sequencing

NSJ: Novel Splice Junction

PDX, Patient Derived Xenograft

PSM: Peptide Spectral Match

QUILTS: Quantitative Integrated Library of Translated SNPs/Splicing

SNV: Single Nucleotide Variant
SUMMARY:

Improvements in mass spectrometry (MS)-based peptide sequencing provide a new opportunity to determine whether polymorphisms, mutations and splice variants identified in cancer cells are translated. Herein we apply a proteogenomic data integration tool (QUILTS) to illustrate protein variant discovery using whole genome, whole transcriptome and global proteome datasets generated from a pair of luminal and basal-like breast cancer patient derived xenografts (PDX). The sensitivity of proteogenomic analysis for singe nucleotide variant (SNV) expression and novel splice junction (NSJ) detection was probed using multiple MS/MS sample process replicates defined here as an independent tandem MS experiment using identical sample material. Despite analysis of over thirty sample process replicates, only about 10% of SNVs (somatic and germline) detected by both DNA and RNA sequencing were observed as peptides. An even smaller proportion of peptides corresponding to NSJ observed by RNA sequencing were detected (<0.1%). Peptides mapping to DNA-detected SNVs without a detectable mRNA transcript were also observed, suggesting that transcriptome coverage was incomplete (~80%). In contrast to germline variants, somatic variants were less likely to be detected at the peptide level in the basal-like tumor than in the luminal tumor raising the possibility of differential translation or protein degradation effects. In conclusion, this large-scale proteogenomic integration allowed us to determine the degree to which mutations are translated and identified gaps in sequence coverage, thereby benchmarking current technology and progress towards whole cancer proteome and transcriptome analysis.
INTRODUCTION:

Massively parallel sequencing (MPS) of cancer genomes has demonstrated enormous complexity, and it is often unclear which somatic mutations drive tumor biology and which are non-functional passenger mutations that passively accumulate. RNA sequencing is frequently used to determine which nucleotide variants are transcribed and therefore have the potential for biological function. However, many mutations detected at the DNA level are not observed at the mRNA level and their observation is dependent upon expression of the stability of the mRNA (1). Mutation detection at the peptide level clearly increases the confidence that any given variant is a potential biological driver and, by assessing peptide levels across all of an individual's polymorphisms, an independent assessment of transcriptome coverage can be obtained.

Integrated proteogenomic methods that combine MPS analysis and proteomics are of particular importance for identifying novel peptides resulting from somatic mutations or inherited polymorphisms. The identification of peptide sequences by mass spectrometry (MS) relies heavily on the quality of the protein sequence database. Use of databases with missing peptide sequences will fail to identify the corresponding peptides within the proteomic data; however, addressing this by including large numbers of irrelevant sequences in the search will decrease sensitivity. Therefore, it is essential that data acquired through MPS is used to create tumor specific databases, incorporating the possibility of variant proteins arising through somatic mutation, inherited polymorphisms, alternatively spliced isoforms and novel expression. The goal of this study was to analyze the flow of information though the central dogma of biology in
an unbiased and comprehensive way to profoundly understand the aberrant information flux that underlies all cancer biology (2-5).

Integrated proteogenomic methodologies have been successfully implemented in several model systems, including mouse and human cell lines (2, 4-7), and in other model systems for gene annotation (3, 8-10). Sample specific DNA databases in MS identification pipelines are a developing tool, but we lack a clear understanding of the proteomic depth and sensitivity required to obtain a truly comprehensive mutant or germline variant peptide identification. To address these issues, we used two patient derived xenograft (PDX) breast cancer models that provided enough material for extensive genomic, transcriptomic and proteomic analyses to determine the capabilities and limitations of MS/MS for novel protein isoforms identification in cancer cells.

EXPERIMENTAL PROCEDURES

Patient Derived Xenograft (PDX) Tumors

Patient-derived xenograft (PDX) tumors from established Basal (WHIM2) and Luminal-B (WHIM16) breast cancer intrinsic subtypes (11) (12) were obtained from the Washington University Human and Mouse-Linked Evaluation of Tumors Core. The tumors were raised subcutaneously in 8 week old NOD.Cg-Prkdc<sup>scid</sup> Il2rg<sup>tm1Wjl</sup>/SzJ mice (Jackson Labs, Bar Harbor, Maine) as previously described (13) (14) and in compliance with NIH regulations and institutional guidelines, and approved by the institutional review board at Washington University. These tumors have significantly different gene expression and proteomic signatures (14) that are related to their intrinsic biology and endocrine signaling. Tumors were harvested and processed to a frozen powder with minimal ischemia time as previously described (15, 16).
Tumors from each animal were harvested by surgical excision at approximately 1.5 cm³ with minimal ischemia time by immediate immersion in a liquid nitrogen bath. The tumor tissues were then placed in pre-cooled tubes on dry ice and stored at -80°C. A tissue “pool” of cryopulverized tumors was prepared in order to generate sufficient material that could be reliably shared and analyzed between multiple laboratories. Briefly, tumor pieces were transferred into pre-cooled Covaris Tissue-Tube 1 Extra (TT01xt) bags (Covaris #520007) and processed in a Covaris CP02 Cryoprep device using different impact settings according to the total tumor tissue weight: <250mg=3; 250-350 mg=4; 350-440 mg=5; 440-550 mg=6. Tissue powder was transferred to an aluminum weighing dish (VWR #1131-436) on dry ice and the tissue was thoroughly mixed with a metal spatula precooled in liquid nitrogen. The tissue powder was then partitioned (~ 100 mg aliquots) into precooled cryovials (Corning #430487). (Note: Cryopulverized tissue will melt if transferred to a plastic weighing boat). All procedures were carried out on dry ice to maintain tissue in a powdered, frozen state.

*Whole genome analysis and RNA sequencing*

Methodologies and data repositories have been published (14). Variant calling using the WGS data were performed by an in house developed pipeline combining several variant calling algorithms (VarScan (17), GATK (18) and Pindel (19)) to achieve better accuracy and sensitivity. For the RNA-Seq analysis, raw FASTQ files were trimmed by 1bp from both ends. All trimmed RNA-Seq reads were aligned to the human reference genome version hg19 using software TopHat version 2.0.3 with --g 1, --bowtie1 (version 0.12.7.0), -M, -x 1, -n 2, --no-coverage-search, and --fusion-search settings to generate BAM files, junction files, and fusion files. Then software TopHat-Fusion (20) version 2.0.3 and ChimeraScan fusion detection (17,
18) (default parameters) were used to generate final potential fusion genes. BedTools and in-house developed software were then used to generate the base pair counts for each exon based on Ensembl annotation file version GRCh37.68 using mapped reads in BAM format.

**Global Proteomics**

Tumor pieces were cryopulverized in pre-cooled Covaris Tissue-Tube 1 Extra (TT01xt) bags and processed in a Covaris CP02 Cryoprep device, with impact setting derived from the weight of the tumor (<250 mg=3; 250-350 mg=4; 350-440 mg=5; 440-550 mg=6). The resulting powder was then transferred to a weighing dish, mixed using a pre-cooled metal spatula and partitioned into ~100 mg aliquots. All procedures were completed on dry ice to maintain sample freezing. Proteins were reduced, alkylated and subjected to trypsin digestion. Peptides were separated using an off-line high pH (7.5 or 10) reversed-phase column and analyzed by Thermo Fisher Q-Exactive and Orbitrap Velos instruments. The iTRAQ analysis was completed by 3 separate sites, and the label free analysis was performed at 2 separate sites. The data is freely available through the CPTAC Data Portal (https://cptacdcc.georgetown.edu/cptac/study/showDetails?accNum=S010).

**Tumor Specific Database Construction**

QUILTS is an publicly available software (quilts.fenyolab.org) which can take in up to 4 inputs for sample-specific database creation: (i) a BED file containing RNA-Seq predicted junctions; VCF files containing (ii) somatic variants and (iii) germline variants; and (iv) a fusion file containing all predicted fusion genes. The output of QUILTS is a protein sequence FASTA file, using either Ensembl or RefSeq as a reference for the hg19 proteome and genome. Example
VCF, BED (http://genome.ucsc.edu/FAQ/FAQformat.html) and fusion input files are available alongside the QUILTS webserver for mock database creation and file formatting.

**Step 1. Creation of Variant Peptide Database:** QUILTS parses out details of variant location and nucleotide change from the variant VCF file for subsequent incorporation into genomic sequences. In cases where both somatic and germline variants are present, tumor specific variants are obtained by filtering out all germline variants from the somatic variant calls. Based on intron/exon boundaries from Ensembl (version 70) or RefSeq (version 20130727), sequences of annotated coding regions are extracted and variant changes were incorporated into these regions based on genomic location. The modified sequences are then translated to proteins in a single reading frame and stored as a FASTA file (Figure 1A). Stop codon removal and insertion due to single amino acid changes were accounted for and highlighted within file output. In this study, even low-quality variants were included in the variant database to allow for validation by mass spectrometric analysis.

**Step 2. Creation of Junction Protein Database:** The RNA-Seq derived junction BED file contains predicted boundaries of adjoining exons (chromosome, intron start, intron end) for each sample. QUILTS filters out splice junctions matching previously annotated boundaries (Ensembl or RefSeq), leaving only novel junction which are split into 3 categories, unannotated alternative splicing (two known exons Figure 1B), completely novel junctions (no known exons Figure 1F, G), and partially novel junctions (one known exon Figure 1C-E). The required frame translation for in silico protein synthesis is indication in Figure 2 for each scenario. Variant peptides are incorporated into the sequences of the alternatively spliced proteins as
described in Step 1 (Figure 1A). In this study, junctions with at least 1 supporting RNA read were included in database creation.

**Step 3. Creation of Fusion Protein Database:** QUILTS translates predicted fusion gene output by a 6 frame translation (Figure 1H). Protein coding regions with more than 6 consecutive amino acids are included in the fusion protein database.

**Experimental Design and Statistical Rational**

Proteowizard (release 2.2.3246 (2012-1-30)) was used to convert raw MS data files to mzML format for downstream data analysis. Peptide spectral matching was then done using the tumor-specific QUILTS databases with the database search engine X! Tandem CYCLONE (2013.02.01.1) using precursor tolerance of 20 ppm and fragment mass tolerances of 20 ppm for high resolution data and 0.4 Da for low resolution data, complete modifications of carbamidomethylated cysteines and iTRAQ 4-plex on peptide N-termini and lysines, potential modifications of oxidation of methionine and deamidation of aspartic and glutamic acid, allowing for 1 missed cleavage. The databases contained a total of 1,078,922 and 1,225,632 tryptic peptides for basal and luminal, respectively. Both databases included a list of external contaminants from cRAP (maintained by the global proteome machine organization) in addition to Ensembl sequences for *Mus musculus*. The search was done against a concatenated database containing mouse and human Ensembl 37.70, cRAP, basal and luminal variant peptides and NSJ peptides. Searches were completed independently for each center (A-E, Table 1) using a simple FDR with separate target-decoy searches which were created through reversal of all protein sequences and searched in combination (21). The FDR was calculated as described by Käll et
al. (22), and was controlled for at a q-value of 0.01 (1%) at the peptide level. The FDR was calculated separately for variant, junction and references peptide. (23) Information detailing identified variant and junction peptides are included (Supplementary Table 4). The data set was also searched against the same databases allowing up to one amino acid substitution per tryptic peptide, and any spectrum that in this search matched better against a variant peptide not detected in the WGS data was removed from the subsequent analysis. Also, peptides with length shorter than eight amino acids were excluded. The results were further filtered on the percentage of the intensity in the fragment mass spectra that were explained by fragmentation of the assigned peptide sequence and only peptides with PSM where larger than 50% of the fragment ion intensity matched to the sequence (all peaks with intensity larger than 1% of the largest fragment peak) were included. Peptides were also required not to have continuous gaps of larger than two amino acids, i.e. peptides with three amino acids in a row without evidence of fragmentation between them were included, but peptides with four or more amino without fragment ions between them were excluded. In addition, if the total number of gaps throughout a peptide exceeded six, the peptide was excluded. The rationale for the filters based on gap size was the observation that commonly when extensive fragmentation is observed for one end of a peptide but not for the other end, the identification is incorrect. In these cases, manual inspection often reveals for high-quality spectra that the search engine has assigned the incorrect sequence, and the correct sequence is missing from the database that was searched.

To assess the quality of the variant peptide identification, the distributions of the fraction of MS/MS intensity explained by the identified peptide, the peptide mass, the e-values, and total fragment ion intensity were compared to the distributions for all identified peptides in the reference protein sequence database (Supplementary Figure 1 A-D, G-J, M-P). Also, the
distribution of the variant (Supplementary Figure 1 E, K, Q) and reference (Supplementary Figure 1 F, L, R) peptides in the four-dimensional space spanning MS/MS intensity explained by the identified peptide, peptide mass, e-value, and total MS/MS intensity were compared. Because no significant difference was observed, we conclude that the FDR for the variant peptides can be accurately estimated using the overall peptide FDR.

Also, for the NSJ peptides the quality was assessed by comparing the distributions of the fraction of MS/MS intensity explained by the identified peptide, the peptide mass, the e-values, and total fragment ion intensity to the distributions for all identified peptides in the reference protein sequence database (Supplementary Figure 2 A-D, F-I, K-N). Also, the distribution of the NSJ (Supplementary Figure 2 E, J, O) and reference (Supplementary Figure 1 F, L, R) peptides in the four-dimensional space spanning MS/MS intensity explained by the identified peptide, peptide mass, e-value, and total MS/MS intensity were compared. Again no significant difference was observed between the NSJ peptides and the reference peptides, indicating that the overall quality of NSJ peptides is close to that of the reference peptides.

In addition, no significant difference was observed for germline and somatic variant peptides (Supplementary Figure 3 A-R) or for variant peptides with or without mRNA evidence (Supplementary Figure 4 A-R).

All the individual peptide spectrum matches are shown in Supplementary Figure 5. The spectra are annotated with the assigned b- and y-ions and neutral losses. The evidence for fragmentation between pairs of amino acids is also shown by annotating the peptide sequence with bars with lengths proportional to the corresponding fragment ion intensity.

For variant and novel peptide identification, a total of 18 iTRAQ and 30 label free sample process replicates (independent tandem MS experiments using identical sample material, were
used to identify sample specific peptides. Peptides with at least 1 peptide spectral match were considered as a positive identification. This is a reasonable assumption because of the stringent filter that includes the requirement of no gaps in the peptide sequence coverage larger than two consecutive amino acid pairs and a maximum of six gaps over the entire peptide. Following identification, peptides matching the reference human, mouse or cRAP proteomes were removed, leaving those peptide, which map only to predicted variant or novel junction peptides. All variant and NSJ peptides were compared to the RefSeq Human + Mouse protein sequence database (downloaded December 1, 2011) to filter out any known peptides which were missed by the original filtering step. Additionally, all novel peptides were compared against the GenBank non-redundant translation database and the neXtProt protein database (24) and all matches were included in the associated tables (Supplementary Table 1 and 2). Peptides with non-redundant matches were included in all analysis except in the creation of highly confident variant and novel junction peptide tables, for which they were removed. For each of the 48 process replicates, the number of unique variant or novel peptides identified was used for titration analysis. Robust regression was used to determine the correlation between total peptides identified and novel/variant peptides in each run. Variants were searched against the dbsnp database (build 142) and the Catalogue Of Somatic Mutations in Cancer (COSMIC) to determine if the genomic variant had been previously identified (Supplementary Table 1C).

As per minimum guidelines for proteogenomic studies, suggested by Nesvizhskii (23), the custom protein sequence databases described here are available at http://openslice.fenyolab.org/data/compref/compref.zip and annotated spectrum for all novel splice junction and single nucleotide variant peptides are provided (Supplementary Figure 5).
RESULTS

PDX tumor lines were generated from primary breast tumors as previously described (25). Two PDX lines (one derived from a luminal tumor, WHIM16 and the other from a basal-like tumor, WHIM2) were included in this study, of which the whole genome sequences (WGS) and RNA-Seq analysis have already been published (13, 14). In the WGS analysis, 40x-50x coverage of 75 bp paired end reads (1.5 x10⁹ - 2 x10⁹) was obtained for germline, tumor and xenograft. RNA-Seq data of 4x10⁸, 75 bp paired end reads were obtained for each xenograft. Global proteome expression was acquired by 18 independent iTRAQ labeled MS/MS sample process replicates (each analysis contained the two luminal and two basal samples, both of which were represented by 2 different reporter ions in the iTRAQ 4-plex) and 15 independent label free MS/MS sample replicate pairs, containing each PDX sample. These experiments were completed across five centers, three using iTRAQ chemical labeling and two using label-free methods (Table 1, Supplementary Figure 6). The number of total peptides, variant peptides and novel junction peptides identified by each center varied based on MS instrumentation, fraction number, and gradient length (Table 1). A total of 184,182 unique human peptides and 9,597 proteins were identified across all data sets, representing the state-of-the-art proteomic coverage available with current techniques. Paired tumor-specific protein databases and corresponding deep proteomics tandem MS data were used to first identify novel protein isoforms involved in breast cancer progression and second to determine the depth of proteomic analysis required to capture comprehensive variant peptide identification.

Variant identification through whole genome sequencing permits the representation of non-synonymous substitutions in our protein sequence database, increasing the number of tumor specific peptides that can be identified by tandem MS (2, 5, 9). Most MS identification methods
rely on reference databases, such as Ensembl, UniProt or RefSeq, for peptide matching. Unfortunately, these databases do not allow novel peptide identification due to variations in the somatic or germline genome. In order to identify tumor specific variant peptides, we used the proteogenomic integration tool QUILTS (Quantitative Integrated Library of Translated SNPs/Splicing), developed specifically for cancer proteome analysis (http://quilts.fenyolab.org). QUILTS uses protein coding variant calls (germline and somatic) and RNA-Seq based junction predictions to build a customized, tumor specific database containing peptide sequences that contain single nucleotide variants and bridging sequences from alternative splicing against the background of a reference human proteome database.

**Variant peptide identification**

Following its construction, each sample-specific database was used to identify tumor and sample specific peptides attributable to both germline and somatic genomic variants. A total of 31,792 basal (26,421 germline and 5,371 somatic) and 28,635 luminal (16,662 germline and 11,973 somatic) variant peptides were predicted by WGS. Of these, we expect only a portion to be both verifiable by MS and also expressed at the mRNA level. The portion of variants identifiable by MS can be predicted based on peptide characteristics known to provide efficient MS identification, including low hydrophobicity and peptide length within 6-30 amino acids. Further, peptides which map to more than one proteomic location are difficult to attribute to a specific gene (26). Therefore, we considered only proteotypic tumor-specific changes with appropriate amino acid lengths as verifiable variant peptides. We found that approximately 3.5% of theoretical variant peptides mapped to more than 1 gene for basal and luminal tumors, which were then removed from subsequent analysis. An additional 32% of all possible variant peptides
were found to be outside of the peptide length limitations for both tumor types. The proportion of variants that are expressed at the mRNA level, however, cannot be easily predicted, and relies on variant calling from whole transcriptome sequencing. Of the approximate 65% of peptides meeting the requirements for MS/MS, a minority had evidence for expression at the mRNA level (30.5% germline basal; 30.7% germline luminal; 10% somatic basal; 19% somatic luminal) (Figure 2A & 2B).

A total of 772 unique variant peptides were identified across all 48 sample process replicates, 119 of which were found by both labeled and label-free analysis, representing a total of 667 genomic SNVs (Supplementary Table 1). Peptide spectral matching of iTRAQ and label free global proteomics data using tumor-specific databases identified a total of 610 basal and 496 luminal variant peptides (including both somatic and germline variants). Each variant peptide contains at least one amino acid change resulting from a genomic SNV, with 8 of the 772 containing two amino acid substitutions, two peptides with three substitutions, and one peptide with five substitutions (Supplementary Table 1). An overwhelming majority of variants identified were represented in dbSNP (96.8%) and neXtProt (76.8%) databases, leaving only 1.8% of identified protein variants being described by neither database. Interestingly, approximately 20% of the variants identified by proteomics analysis lacked mRNA evidence based on RNA-Seq variant calling (Figure 2B). This can be explained, at least partially, by the limitations associated with variant calling from RNA-Seq data, due to the inherent complexity of the transcriptome (27).

Of the 610 variant peptides in the basal tumor, 605 were due to germline variants and only 5 were due to somatic variants (Figure 2C). Two of the five basal somatic variants were identified by RNA-seq, one in the transcription factor GTF3C3 (ALGYMEGAESYGK) and
one in the nucleoprotein AHNAK2 (SFGVLAPGK) (Supplementary Table 1A). In the luminal tumor, 140 somatic and 356 germline variant peptides were identified and more than 70% of the luminal somatic variants were found at the mRNA level. The difference in somatic variant expression between the basal and the luminal is considerable, implicating differential translation or increased protein degradation effects in the basal tumor. While approximately 1/3 of the variant peptides were only identified by only one spectral match across all MS/MS runs, 20% had ten or more associated peptide spectral matches (PSMs) indicating consistently observable expression levels (Figure 2C, Supplementary Table 1). Additionally, comparison of the proteomic variants with predicted SNVs in 105 of the breast TCGA tumors chosen for analysis by CPTAC found that 89% of the same genomic variants were present at the DNA level in at least one of the human breast tumors (Supplementary Table 1).

We identified a subset of highly confident somatic variant peptides that had more than 10 peptide spectral matches identified in at least one process replicate, associated RNA expression and evidence for expression in the associated protein (100+ PSM along the protein) (Table 2). Fifteen variants were identified as tumor specific (somatic only) with high confidence, including variants in Keratin19 (ENSP00000408759: A60G), the mannose-6 phosphate receptor-binding protein Perilipin-3 (ENSP00000465596: V275A), and the Interferon Regulatory Factor binding protein IRF2BP2 (ENSP00000355569: V275A) (Table 2).

In order to determine the number of sample process replicates that are required to identify the maximum number of translated variants, we completed a titration analysis using 18 global iTRAQ and 28 label free low resolution MS/MS experiments. We demonstrated that additional MS analysis would likely result in further variant peptide identification (Figure 3A &3B). The number of total peptides identified in these replicates varied between 19,720 to 125,912 for...
iTRAQ labeled and 10,506 to 33,091 for label-free MS/MS and the identification of variant peptides correlated to the total number of total peptides identified in each replicate (iTRAQ: \( r^2=0.665 \); Label free: \( r^2=0.745 \)). Despite this correlation, even process replicates with the highest peptide identifications identified less than 40% of the total unique variant peptides observed. (Supplementary Figure 7A & 7B).

**Novel Junction Peptide Identification**

In addition to amino acid changes resulting from SNVs, alternative splicing and novel expression have been shown to effect tumor growth and disease progression (28). Intron/exon boundaries determined by RNA-Seq analysis were used to identify unannotated alternative splicing events (matching to two known exons **Figure 1B**), partially novel splicing (matching to only one known exon **Figure 1C-E**), and completely novel splicing (matching to no known exons **Figure 1F-G**) occurring in basal and luminal PDX tumors. The number of MS verifiable peptides, being both the appropriate length and gene specific, was identified to determine the full proteomic potential due to novel splice junction (NSJ) peptides. Two percent of unannotated alternative splicing peptides, 1.3% of partially novel splicing peptides and less than 0.01% of completely novel peptides were removed from the analysis due to their mapping to other known genes. An additional ~24% of novel junction peptides were found to be outside of the MS peptide length limitations (**Figure 4A**). Based on this analysis, we predicted a total of 22,187 and 20,442 unannotated alternative splicing peptides, 217,715 and 180,100 partially novel junction peptides and 238,891 and 164,273 completely novel peptides to be verifiable by MS for luminal and basal, respectively (**Figure 4A**). Using these custom databases for spectral matching, were
able to identify less than 0.05% of the novel junction peptides for both basal and luminal tumors (Figure 4B).

We included all RNA-Seq junction predictions as input for protein database creation, without taking into account the number of reads supporting each junction. We used this liberal inclusion in to create the most complete database with the available MPS data, containing all possible proteomic changes, with the idea that the proteomic data can be used to filter through transcriptional false positives. It is likely, however, that junctions confidently identified by proteomics analysis will have more supporting reads. We therefore considered the number of junction reads supporting these peptides post-processing and found that novel junctions with MS identifications had significantly more RNA sequencing reads (median reads basal=11, luminal=6) compared to all junctions in the protein database (median reads basal=2, p=1.8e-4; luminal=2, p=2.898e-5). Upstream filtering of junction data containing 5 or more supporting reads drastically reduced our predicted novel junction peptide number to 76,053 basal and 91,609 luminal peptides and approximately 50% of novel junction peptides identified by MS/MS met this criteria (80 of the 129 basal and 68 of the 147 luminal peptides) (Figure 4B). The ratio of peptides identified to peptides predicted was similar between each of the three junction classes (Supplementary Figure 8).

A total of 86 unique novel splice junction (NSJ) peptides were identified in by least one sample process replicate. Of the 66 NSJ peptides identified in basal tumors, 8 support unannotated alternative splicing, 32 indicated splicing of a known exon with a novel coding region and 26 demonstrating the splicing of two novel exons. Similarly, 7 peptides supporting splicing of two known exons, 34 with one known exon and 26 completely novel exon splicing events were identified in luminal tumors. Of these approximately 50% of the NSJ peptides were
identified in both basal and luminal tumors (Supplementary Table 2). Approximately half of novel junction peptides were supported by only one peptide spectral match by only one process replicate (Figure 4C).

We identified 16 novel junction peptides we considered to be highly confident, having at least five peptide spectral matches, more than five supporting RNA read, and evidence for protein expression in the associated gene (>50 PSMs) (Table 3). In a few cases, NSJ peptide appeared to be present in both the basal and the luminal tumor, i.e. iTRAQ reporter ions were observed for both samples and RNA-Seq evidence existed for both samples. In these cases, the sample is listed as both basal and luminal, but sometimes the identification from label free analysis was able to determine the sample of origin. The peptide with the most evidence (highest PSM count) was found for a novel coding region near BHMT2 in luminal tumors (Supplementary Table 2).

We completed similar titration analysis shown for the variant peptides, to find the number of unique novel peptides cumulatively identified with each process replicate. As seen with the variant data, spectra from all replicates were required to attain the complete list of junction peptides in both iTRAQ and label-free analysis (Figure 3C-D). The novel peptide identification was similarly correlated with total peptides identified than that seen with the variant peptide identification, with an R-squared value of 0.561 for iTRAQ and 0.385 for label free tandem MS. Our results establish that the extent of novel and variant peptide identification is highly dependent on the depth of proteomic analysis, and advancements in MS sensitivity will result in more comprehensive variant peptide identification. To better understand this continued rise in SNV and NSJ peptides with increasing process replicate runs, we plotted a titration for reference peptide identification for iTRAQ and label free MS/MS (Supplementary Figure 9). This
analysis found a similar increase in reference peptide identification with each successive iTRAQ process replicate, though the label free curve leveled out after approximately 12 replicate MS/MS runs. This indicates that increasing the number of process replicates run, particularly using different platforms and methodologies, can identify a wider range of novel peptides.

Although splicing and variants were considered simultaneously in our tumor specific databases, no peptides containing both a novel junction and SNV were identified from our analysis. We also used QUILTS to incorporate novel peptides from a 6-frame translation of 38 gene fusion calls, 13 in basal and 25 in luminal. A total of 954 luminal fusion peptides and 483 basal fusion peptides were included in the protein sequence search database, but no positive identifications were found using our proteomics analysis. We expect this is, in part, a probabilistic issue, with relatively few potential fusion proteins represented in the protein sequence database. Although no fusion proteins were identified, of the forty fusion gene junctions found within a known gene boundary, 26 had some evidence of protein expression (PSM>0 along the protein) (Supplementary Table 3).

DISCUSSION

The field of proteogenomics has seen considerable growth in the last 5 years requiring a focus on the integration of genomics and proteomics through peptide mapping and the use of sequencing data to attain a comprehensive view of the proteome. Tools which utilize MPS data to better annotate and identify proteins are essential for broad protein identification. Ideally, integration of sequencing and proteomic analysis will vastly improve our understanding of complex biological systems, in that more comprehensive and diverse data from the same system can provide a clearer view of its biological landscape. Additionally, integrating multiple datasets
can supplement the limitations associated with each method. For example, proteomics can be 
used to better annotate the protein coding regions of the genome (3, 8-10); DNA sequencing can 
predict protein coding variants in MS/MS(4); and RNA-Seq transcriptomics can supplement MS 
proteomic coverage (5, 6, 29).

This study demonstrates the current advantages and limitations of proteogenomic 
integration for interpreting cancer biology, specifically in the detection of novel protein isoforms.
We determined the capacity of current MS proteomic methods for variant and novel peptide 
identification in a sample that has undergone both extensive proteomic (48 global MS/MS 
sample process replicates) and DNA/RNA MPS analysis. Though the ability to detect more than 
700 peptides that confirm the expression of single nucleotide variations and 86 novel splicing 
events is notable, no one MS replicate was able to recover more than 40% of the full list of 
observable peptides, regardless of the instrumentation or methodology used. Further, titration 
curves for both variant and junction peptide analysis suggest that increased experimental process 
replicates would continue to increase the number of captured novel peptides (Figure 3).

Although the sensitivity of MS-based proteomics has improved dramatically, the limited 
dynamic range of the analysis is obviously still an issue. For example, variant peptides of 
established breast cancer genes such as PIK3CA or TP53 were not detected in this study. Since 
peptide size and physiochemical properties have large effects on ionization and fragmentation 
(30), i.e. because some peptides are well suited for MS analysis while others are not, some issues 
with low protein coverage are currently unavoidable using tandem MS approaches. In addition, 
the overall dynamic range of the analysis is several orders of magnitude lower than the range of 
protein concentrations, even when extensive separation of peptides is performed. This is due to a 
low MS dynamic range, being only four orders of magnitude for a given measurement, and a
known bottleneck in instrument speed (31). Although greater fractionation may partially resolve
the issue, this approach is limited by sample quantity. Advancements in MS protein
identification sensitivity must be made, either through improvements in sample preparation,
instrumentation sensitivity and speed and identification algorithms, if we are to ultimately
achieve complete proteomic landscape.

The low recovery between predicted novel junction peptides and those identified in the
proteomics data is particularly striking (Figure 4B) and similar levels of discovery have been
reported in other mammalian systems (5). This supports the notion that there is a substantial
level of noise in the transcriptome, i.e. many transcripts never result in stable proteins. Thus
proteomics becomes an essential technology in validating novel protein isoforms and splice sites.
This result also points to the high quality of the human genomic annotation, with minimal novel
exon discoveries despite the great depth in sequencing and proteomics. Further, the overlap in
novel junction peptides identified in the luminal and basal tumors (Supplementary Table 2)
indicates that these peptides may correlate to either “normal” exon structure, or instead may be
attributed to a more cancer specific splicing activity.

This study also demonstrates the current advantages and limitations in DNA/RNA MPS
analysis. A portion of the peptides spanning novel junctions were only supported by a one or a
few RNA-Seq but had strong MS peptide evidence. Similarly many variants had only low quality
score from WGS or did not have supporting RNA-Seq evidence, but had strong MS evidence.
This makes proteomics the method of choice for determining which variants will be incorporated
into stable proteins or cause protein misfolding and degradation and in the search for drivers of
cancer.
The paucity of translated somatic variants in the basal-like sample in comparison to the luminal tumor should be further investigated in larger data sets. Translational controls and degradation mechanisms may in play to restrict the repertoire of mutant genes that are translated and these maybe another source of inter-tumor heterogeneity.

CONCLUSIONS

Proteomics is essential in validating genomic changes including SNVs and novel splicing to assess the degree to which these genomic alterations are translated and therefore biologically active. Although peptide coverage is restricted by current technologies, with only 10% coverage of variant peptide sequence even with multiple fractions and process replicates, our ability to validate genomic variation in cancer using proteomics is still substantial. This low variant peptide coverage may occur for several reasons. Tryptic digestion is clearly one limitation and the use of additional enzymes and fractionation approaches are under investigation. The low rates of peptide detection may not just be a sensitivity issue but reflect biological effects. For example, the very low detection rates for novel splicing events may reflect the fact that many are not efficiently translated or quickly degraded. Similarly, lack of peptide expression for some SNV may be due to somatic mutation driven translational effects or protein instability/degradation. The application of proteogenomic integration methods to larger data sets and improvements in peptide identification and MS/MS sensitivity will help clarify these issues in the future.

ACKNOWLEDGMENTS
This work was supported by National Cancer Institute (NCI) CPTAC awards U24CA159988, U24CA160019, U24CA160034, U24CA160035, U24CA160036 and by CPTAC contract 13XS068 from Leidos Biomedical Research, Inc. This work has utilized computing resources at the High Performance Computing Facility of the Center for Health Informatics and Bioinformatics at the NYU Langone Medical Center.

NATIONAL CANCER INSTITUTE CLINICAL PROTEOMICS TUMOR ANALYSIS CONSORTIUM (NCI CPTAC) INVESTIGATORS

Broad Institute of MIT and Harvard

Steven A. Carr  
Michael A. Gillette  
Karl R. Klauser  
Eric Kuhn  
D.R. Mani  
Philipp Mertins

Enterprise Science and Computing, Inc.

Karen A. Ketchum

Fred Hutchinson Cancer Research Center

Amanda G. Paulovich  
Jeffrey R. Whiteaker

Georgetown University

Nathan J. Edwards  
Subha Madhavan  
Peter B. McGarvey

Icahn School of Medicine at Mount Sinai

Pei Wang

Johns Hopkins University

Daniel Chan
Akhilesh Pandey
Ie-Ming Shih
Hui Zhang
Zhen Zhang
Heng Zhu

Leidos, Inc.

Gordon A. Whiteley

Massachusetts General Hospital and Harvard University

Steven J. Skates

Massachusetts Institute of Technology

Forest M. White

Memorial Sloan Kettering Cancer Center

Douglas A. Levine

National Cancer Institute

Emily S. Boja
Christopher R. Kinsinger
Tara Hiltke
Mehdi Mesri
Robert C. Rivers
Henry Rodriguez
Kenna M. Shaw

National Institute of Standards and Technology

Stephen E. Stein

New York University

David Fenyo

Pacific Northwest National Laboratory

Tao Liu
Jason E. McDermott
Samuel H. Payne
Karin D. Rodland
Richard D. Smith

Spectragen-Informatics

Paul Rudnick

Stanford University

Michael Snyder

University of Chicago

Yingming Zhao

University of North Carolina at Chapel Hill

Xian Chen
David F. Ransohoff

University of Washington

Andrew N. Hoofnagle

Vanderbilt University

Daniel C. Liebler
Melinda E. Sanders
Zhiao Shi
Robbert J.C. Slebos
David L. Tabb
Bing Zhang
Lisa J. Zimmerman

Virginia Tech

Yue Wang

Washington University in St. Louis

Sherri R. Davies
Li Ding
Matthew J. Ellis
R. Reid Townsend
REFERENCES


FIGURE LEGENDS

Figure 1. QUILTS processing of different variant scenarios. QUILTS treats each potential splicing situation differently, in terms of how many frames are translated into protein. Single amino acid changes resulting from germline or somatic variants require only 1 reading frame (A). Junction-based changes include unannotated alternative splicing with conserved exon boundaries (B), truncation of an exon (C), and elongation of an exon within an intron (D), all with conserved reading frame. For elongation of an exon in the intergenic space (E) and regions of novel expression (F), frame translation is determined based on whether or not the novel exon boundary is up or downstream of the annotated exon. Junctions showing completely novel expression require a 6 reading frame translation (B). Fusion genes (H) are also translated in 6 frames. Situations with insertion or deletion of nucleotides are treated as junction changes as indicated above (B-D).

Figure 2. Single nucleotide variant (SNV) peptide expression in basal and luminal tumors. (A) Predicted proteomic change based on single nucleotide variants. Purple bars show the number of predicted unique peptides based on DNA variants which were also detected by RNA-Seq, blue bars indicate the number of predicted unique peptides based on DNA variants which were not detected by RNA-Seq and grey bars indicate those peptides which are not detectable by mass spectrometry techniques due to size limitations (*peptides which have lengths <6 or >30 amino acids). (B) Proportion of DNA variants which were also identified by RNA sequencing and MS/MS proteomics for luminal and basal breast tumors. (c) Total basal and luminal variant peptides identified by MS/MS. Identification by iTRAQ, label free MS/MS or both is indicated by stacked bar color.
**Figure 3. Titration analysis of SNV and novel junction peptide discovery.** Titration to determine the number of tandem MS process replicates needed to identify all variant peptides for iTRAQ (A) and label free (B) and novel junction peptides for iTRAQ (C) and label free (D) MS/MS. iTRAQ center A corresponds to process replicates 2, 3, 8, 10, 11, 13 and 14; center B replicates 4, 6, 9, 15, 16 and 18; and center C replicates 1, 5, 7, 12, 17. Only label-free analysis from center E was used in this analysis (B, D). Basal and luminal tumor peptide identifications were pooled for titration analysis. Total list of SNV and novel junction peptides are included in Supplementary Tables 1-2.

**Figure 4. Novel peptide expression in basal and luminal tumors.** (A) Predicted proteomic change based on novel junction peptides. Grey bars indicates variant tryptic peptides with peptides with lengths <6 or >30 and orange/purple/green bars show the number of unique peptides which are verifiable by MS (B) Proportion of predicted junctions based on RNA sequencing (all junctions, purple; junctions 5+ reads, blue) which were identified by MS/MS proteomics for luminal and basal breast tumors (C) Total basal and luminal junction peptides identified. Identification by iTRAQ, label free MS/MS or both is indicated by stacked bar color.
TABLES

Table 1. Mass spectrometry metrics and methodology by center. Proteome analysis of basal and luminal PDX tumors was completed across 5 centers (A-E) using Thermo Fisher Q-Exactive or Orbitrap Velos instrumentation. The number of fractions, LC-MS/MS gradient length, MS/MS model, number of PDX sample process replicates and the average number unique total, single nucleotide variant (SNV) and novel junction (NSJ) peptides are given for each center. All 5 centers used bRPLC for LC-MS/MS separation.

<table>
<thead>
<tr>
<th>Resolution</th>
<th>iTRAQ</th>
<th>Label-Free</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>High</td>
</tr>
<tr>
<td>Center</td>
<td></td>
<td>A</td>
</tr>
<tr>
<td>Instrument</td>
<td></td>
<td>Q-Exactive</td>
</tr>
<tr>
<td>Fractions</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Replicates</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>Gradient (min)</td>
<td>110</td>
<td>90</td>
</tr>
<tr>
<td>Total Peptides</td>
<td>143,790</td>
<td>75,440</td>
</tr>
<tr>
<td>SNV Peptides</td>
<td>642</td>
<td>267</td>
</tr>
<tr>
<td>NSJ Peptides</td>
<td>52</td>
<td>13</td>
</tr>
</tbody>
</table>